Giuseppe Cabibbo

University of Palermo

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

ORCID

Google Scholar

Academic Page

Articles (29)

Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis

Article Link

Year:

2025

Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study

Article Link

Year:

2025

Hepatocellular carcinoma in people living with HIV

Article Link

Year:

2025

Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma

Article Link

Year:

2025

Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison

Article Link

Year:

2025

The “shell game” after objective response in patients with advanced HCC treated with immunotherapy

Article Link

Year:

2025

Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies

Article Link

Year:

2025

Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Article Link

Year:

2025

Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

Article Link

Year:

2025

Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices

Article Link

Year:

2024

What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis

Article Link

Year:

2024

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Article Link

Year:

2024

Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma

Article Link

Year:

2024

Reply to: “irLI or not irLI: That is the question”

Article Link

Year:

2024

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Article Link

Year:

2024

Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments

Article Link

Year:

2024

Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

Article Link

Year:

2024

The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma

Article Link

Year:

2023

Analysis of individual patient data in patients with HCC treated with immunotherapy: A step forward for clinical trial design

Article Link

Year:

2023

Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Article Link

Year:

2023

Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology

Article Link

Year:

2023

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Article Link

Year:

2022

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

Article Link

Year:

2022

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals

Article Link

Year:

2022

Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function

Article Link

Year:

2022

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Article Link

Year:

2022

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Article Link

Year:

2022

Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma

Article Link

Year:

2021

The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma

Article Link

Year:

2021

Collaborators (12)

Alessandro Vitale

University of Padua

ITALY

Yujin Hoshida

University of Texas Southwestern Medical Center

UNITED STATES

Ferran Torres

Universitat Autònoma de Barcelona (UAB)

SPAIN

Julien Edeline

PU-PH - Full Professor

Université de Rennes 1 Faculté de Médecine

FRANCE

Gabriele Di Maria

University of Palermo

ITALY

Maria Reig

Head of the Liver Oncology group-CIBER

SPAIN

Franco Trevisani

University of Bologna

ITALY

Francesco Paolo Russo

Padua University Hospital

ITALY

Luca Rinaldi

University of Molise

ITALY

Paolo Gallo

Università Campus Bio-Medico

ITALY

Giovanni Galati

Campus Bio Medico University Hospital

ITALY

Lorenza Rimassa

Humanitas University

ITALY

Giuseppe Cabibbo

Research Interests

Explore related searches

Contact this professor

Articles (29)

Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis

Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study

Hepatocellular carcinoma in people living with HIV

Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma

Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison

The “shell game” after objective response in patients with advanced HCC treated with immunotherapy

Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies

Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death

Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices

What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma

Reply to: “irLI or not irLI: That is the question”

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma

Analysis of individual patient data in patients with HCC treated with immunotherapy: A step forward for clinical trial design

Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals

Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma

The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma

Collaborators (12)

Alessandro Vitale

Yujin Hoshida

Ferran Torres

Julien Edeline

Gabriele Di Maria

Maria Reig

Franco Trevisani

Francesco Paolo Russo

Luca Rinaldi

Paolo Gallo

Giovanni Galati

Lorenza Rimassa

How do I reach out?

Meet Kite AI